End Stage Kidney Disease clinical trials

Explore recruiting end stage kidney disease clinical trials.

Recruiting end stage kidney disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

End Stage Kidney Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

DAPA-ICU Trial - Dapagliflozin for cardio-renal protection after ICU discharge. A prospective, randomized, double blinded, multicenter study

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Study to Evaluate the Efficacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis (ELIXIR)

Sweden, Spain, Germany, Denmark, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

PROPHYLACTIC ANTIBIOTIC TREATMENT IN END-STAGE KIDNEY DISEASE AND CENTRAL VENOUS CATHETER AS HEMODIALYSIS VASCULAR ACCESS

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Pilot Study to Evaluate Safety and Efficacy of PolyCore, a Ternary Combination of Xylitol, L-Carnitine and Polydextrin, to Treat End-Stage Kidney Disease Patients Starting Peritoneal Dialysis (EXCITE)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Study of Glucothera Plus for Peritoneal Dialysis in Children (ASTRA)

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Comparison of treatment completion rates with three short-course rifamycin-based regimens (three months of daily isoniazid plus rifampicin [3HR], three months of once-weekly isoniazid plus rifapentine [3HP], and four months of daily rifampicin [4R]) for treatment of latent tuberculosis infection in patients with end-stage kidney disease: A randomised controlled clinical trial (RIFAKiD-TB Trial)

Spain

Therapeutic use (Phase IV) EU CTIS Study details

End Stage Kidney Disease trials by city

End Stage Kidney Disease in Toronto End Stage Kidney Disease in Vancouver End Stage Kidney Disease in Montreal End Stage Kidney Disease in Calgary End Stage Kidney Disease in Edmonton End Stage Kidney Disease in Ottawa End Stage Kidney Disease in Winnipeg End Stage Kidney Disease in Quebec City End Stage Kidney Disease in Hamilton End Stage Kidney Disease in Kitchener End Stage Kidney Disease in London End Stage Kidney Disease in Halifax End Stage Kidney Disease in New York End Stage Kidney Disease in Los Angeles End Stage Kidney Disease in Chicago End Stage Kidney Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease